105 related articles for article (PubMed ID: 20126983)
1. The molecular mechanism of Vav3 oncogene on upregulation of androgen receptor activity in prostate cancer cells.
Liu Y; Wu X; Dong Z; Lu S
Int J Oncol; 2010 Mar; 36(3):623-33. PubMed ID: 20126983
[TBL] [Abstract][Full Text] [Related]
2. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
Dong Z; Liu Y; Lu S; Wang A; Lee K; Wang LH; Revelo M; Lu S
Mol Endocrinol; 2006 Oct; 20(10):2315-25. PubMed ID: 16762975
[TBL] [Abstract][Full Text] [Related]
3. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
Lyons LS; Burnstein KL
Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
[TBL] [Abstract][Full Text] [Related]
4. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer.
Rao S; Lyons LS; Fahrenholtz CD; Wu F; Farooq A; Balkan W; Burnstein KL
Oncogene; 2012 Feb; 31(6):716-27. PubMed ID: 21765461
[TBL] [Abstract][Full Text] [Related]
5. Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer.
Lee K; Liu Y; Mo JQ; Zhang J; Dong Z; Lu S
BMC Cancer; 2008 Jun; 8():158. PubMed ID: 18518979
[TBL] [Abstract][Full Text] [Related]
6. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
Lyons LS; Rao S; Balkan W; Faysal J; Maiorino CA; Burnstein KL
Mol Endocrinol; 2008 Mar; 22(3):597-608. PubMed ID: 18079321
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H
Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222
[TBL] [Abstract][Full Text] [Related]
8. Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
Dong Z; Liu Y; Levin L; Oleksowicz L; Wang J; Lu S
Oncol Rep; 2011 Jun; 25(6):1511-6. PubMed ID: 21455584
[TBL] [Abstract][Full Text] [Related]
9. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
10. Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.
Wu F; Peacock SO; Rao S; Lemmon SK; Burnstein KL
J Biol Chem; 2013 Feb; 288(8):5463-74. PubMed ID: 23281476
[TBL] [Abstract][Full Text] [Related]
11. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
12. Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
Magani F; Peacock SO; Rice MA; Martinez MJ; Greene AM; Magani PS; Lyles R; Weitz JR; Burnstein KL
Mol Cancer Res; 2017 Nov; 15(11):1469-1480. PubMed ID: 28811363
[TBL] [Abstract][Full Text] [Related]
13. The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia.
Hirai K; Nomura T; Yamasaki M; Inoue T; Narimatsu T; Chisato Nakada PD; Yoshiyuki Tsukamoto PD; Matsuura K; Sato F; Moriyama M; Mimata H
Urol Oncol; 2014 Feb; 32(2):101-9. PubMed ID: 23403204
[TBL] [Abstract][Full Text] [Related]
14. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.
Deep G; Oberlies NH; Kroll DJ; Agarwal R
Oncogene; 2008 Jun; 27(28):3986-98. PubMed ID: 18332867
[TBL] [Abstract][Full Text] [Related]
15. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
17. PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells.
Ikezoe T; Chen SS; Yang Y; Heber D; Taguchi H; Koeffler HP
Int J Oncol; 2003 Nov; 23(5):1461-70. PubMed ID: 14532991
[TBL] [Abstract][Full Text] [Related]
18. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
Dulinska-Litewka J; McCubrey JA; Laidler P
Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
[TBL] [Abstract][Full Text] [Related]
19. Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer.
Liu Y; Mo JQ; Hu Q; Boivin G; Levin L; Lu S; Yang D; Dong Z; Lu S
Cancer Res; 2008 Aug; 68(15):6396-406. PubMed ID: 18676865
[TBL] [Abstract][Full Text] [Related]
20. PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells.
Lu S; Ren C; Liu Y; Epner DE
Int J Oncol; 2006 Jan; 28(1):245-51. PubMed ID: 16328002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
